Spruce Biosciences Inc Quick Ratio (SPRB) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Spruce Biosciences Inc   (NASDAQ: SPRB)

Spruce Biosciences Inc 's Quick Ratio

SPRB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 8.78 below Spruce Biosciences Inc average.

Within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Quick Ratio than Spruce Biosciences Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 120 to 335.

Explain Quick Ratio?
How much Cash & cash equivalents SPRB´s has?
What are SPRB´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SPRB Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 526.46 % 14.24 % -67.67 % -83.77 % -87.75 %
Y / Y Cash & cash equivalent Change 487.66 % 111.13 % 26.2 % -82.23 % -76.48 %
Quick Ratio MRQ 8.78 14.68 51.86 5.54 9.36
SPRB's Total Ranking # 335 # 120 # 831 # 562 # 665
Seq. Current Liabilities Change 197.66 % 290.56 % -51.01 % 10 % -45.72 %
Seq. Cash & cash equivalent Change 78.07 % 10.58 % 358.39 % -34.89 % -36.03 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 187
Overall Market # 524


Quick Ratio Statistics
High Average Low
52.36 19.74 0.88
(Jun 30 2021)   (Dec 31 2019)




Financial Statements
Spruce Biosciences Inc 's Current Liabilities $ 11 Millions Visit SPRB's Balance sheet
Spruce Biosciences Inc 's Cash & cash equivalent $ 96 Millions Visit SPRB's Balance sheet
Source of SPRB's Sales Visit SPRB's Sales by Geography


Cumulative Spruce Biosciences Inc 's Quick Ratio

SPRB's Quick Ratio for the trailling 12 Months

SPRB Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -11.32 % -74.29 % -77.9 % -82.79 % -65.8 %
Y / Y Cash & cash equivalent TTM Growth 49.11 % -33 % -59.31 % -70.24 % -60.36 %
Quick Ratio TTM 11.99 15.67 12.95 9.31 7.13
Total Ranking TTM # 475 # 733 # 640 # 437 # 351
Seq. Current Liabilities TTM Growth 110.99 % 5.85 % -20.11 % -50.3 % -38.83 %
Seq. Cash & cash equivalent TTM Growth 61.45 % 28.02 % 11.11 % -35.07 % -27.46 %

Quick ratio ranking by company, industry and sector >> Back to SPRB Financial Strength Comparisons >> Go to Compare SPRB Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $10.96 millions, cumulative Quick Ratio decreased to 11.99 above the SPRB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 422 other companies have achieved higher Quick Ratio than Spruce Biosciences Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2638.

Explain Quick Ratio?
How much Cash & cash equivalents SPRB´s has?
What are SPRB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 423
Healthcare Sector # 860
Within the Market # 335


trailing twelve months Quick Ratio Statistics
High Average Low
13.55 5.27 1.89
(Sep 30 2021)   (Sep 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Neuphoria Therapeutics Inc   23.89 $ 19.866  Millions$ 0.832  Millions
Innoviva Inc   23.77 $ 1,118.871  Millions$ 47.064  Millions
Pepgen Inc   23.51 $ 211.674  Millions$ 9.005  Millions
Kailera Therapeutics Inc   23.41 $ 1,958.240  Millions$ 83.651  Millions
Equillium Inc   23.07 $ 57.164  Millions$ 2.478  Millions
Relmada Therapeutics Inc  21.72 $ 217.731  Millions$ 10.023  Millions
Keros Therapeutics Inc   21.20 $ 257.606  Millions$ 12.153  Millions
Protagonist Therapeutics inc   21.05 $ 782.576  Millions$ 37.181  Millions
Stablecoin Development Corporation  20.76 $ 7.122  Millions$ 0.343  Millions
Rhythm Pharmaceuticals Inc   20.65 $ 596.183  Millions$ 28.868  Millions
Structure Therapeutics Inc   20.31 $ 1,342.700  Millions$ 66.113  Millions
Scynexis Inc   19.69 $ 114.696  Millions$ 5.825  Millions
Q32 Bio Inc   19.68 $ 106.270  Millions$ 5.401  Millions
Damora Therapeutics Inc   19.62 $ 540.515  Millions$ 27.550  Millions
Kairos Pharma Ltd   19.12 $ 5.067  Millions$ 0.265  Millions
Minerva Neurosciences Inc   19.02 $ 75.267  Millions$ 3.958  Millions
Abcellera Biologics Inc   18.05 $ 960.143  Millions$ 53.189  Millions
Sellas Life Sciences Group Inc   17.29 $ 138.443  Millions$ 8.006  Millions
Whitehawk Therapeutics Inc   17.17 $ 190.000  Millions$ 11.069  Millions
Forte Biosciences Inc   17.12 $ 347.331  Millions$ 20.289  Millions
Ovid Therapeutics Inc   17.01 $ 169.769  Millions$ 9.980  Millions
Bioage Labs Inc   16.59 $ 318.745  Millions$ 19.217  Millions
Olema Pharmaceuticals Inc   16.48 $ 873.571  Millions$ 53.014  Millions
Erasca Inc   16.41 $ 610.496  Millions$ 37.200  Millions
Janux Therapeutics Inc   16.14 $ 970.913  Millions$ 60.152  Millions
Edgewise Therapeutics inc   15.86 $ 460.709  Millions$ 29.042  Millions
Corvus Pharmaceuticals Inc   15.74 $ 215.200  Millions$ 13.672  Millions
Telomir Pharmaceuticals Inc   15.55 $ 5.170  Millions$ 0.332  Millions
Rapport Therapeutics Inc   15.34 $ 436.077  Millions$ 28.424  Millions
Lb Pharmaceuticals Inc  15.32 $ 369.576  Millions$ 24.128  Millions

Date modified: 2026-09-12T06:24:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.